

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE13a-16 OR 15d-16 UNDERTHE SECURITIES EXCHANGE ACT OF 1934 Forthe month of December, 2024 CommissionFile Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrantâ€™s name into English) 1701-1702, China Central Office Tower 1No. 81 Jianguo Road, Chaoyang DistrictBeijing, 100025Peopleâ€™s Republic of China(Address of principal executive office) A Indicateby check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. A Form 20-F A x A Form 40-F A A A A A CASIPharmaceuticals Received Termination Process Letter for License of EvomelaÂ® from AcrotechÂ OnDecember 13, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (â€œCASIâ€ or the â€œCompanyâ€)received a Termination Process Letter from Acrotech Biopharma Inc. (â€œAcrotechâ€) of certain License Agreement (the â€œLicenseAgreementâ€), dated September 17, 2014, between Spectrum Pharmaceuticals, Inc. and the Company granting the exclusive rights to theCompany to commercialize EvomelaÂ® in China, which was later assigned to Acrotech on March 1, 2019. Acrotech alleged insuch letter that the Company materially breached the License Agreement and failed to cure such breach, and the License Agreement was thereforeterminated. Pursuant to the License Agreement, the Company can continue to distribute and sell EvomelaÂ® for a reasonablewind-down period not to exceed 24 months, so the Company does not expect any disruption to its current distribution plan for EvomelaÂ®during such period. A TheCompany categorically rejects any alleged basis of termination in Acrotechâ€™s letter, believes that the purported termination isinvalid, and is actively reviewing its options under the current circumstances, including without limitation to continue communicatingwith Acrothech with respect to this matter. It is not possible at this early stage to predict how the matter would be resolved by theparties. A Forward-Looking Statements A This 6-K contains forward-looking statements.These statements are made under the â€œsafe harborâ€ provisions of the U.S. Private Securities Litigation Reform Act of 1995.These forward-looking statements can be identified by terminology such as â€œwill,â€ â€œexpects,â€ â€œanticipates,â€ â€œfuture,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œestimates,â€ â€œconfidentâ€ and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securitiesand Exchange Commission (the â€œSECâ€), in its annual report to shareholders, in press releases and other written materials andin oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, includingstatements about the Companyâ€™s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherentrisks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-lookingstatement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-lookingstatement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements containedherein. A A SIGNATURES A Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. A A CASI Pharmaceuticals, Inc. A A A By: /s/ Wei-Wu He A Name: Wei-Wu He A Title: Chairman & CEO A A Date: December 16, 2024 A A A A A